Laboratory of Molecular Modelling, Department of Chemistry, Federal University of Lavras, Lavras37200-000, MG, Brazil.
Department of Chemistry, Faculty of Science, University of Hradec Králové, Hradec Králové500 03, Czech Republic.
J Phys Chem B. 2023 Jan 19;127(2):495-504. doi: 10.1021/acs.jpcb.2c07147. Epub 2023 Jan 5.
A large part of the world's population is affected by Alzheimer's disease (AD) and diabetes mellitus type 2, which cause both social and economic impacts. These two conditions are associated with one protein, AMPK. Studies have shown that vanadium complexes, such as bis(','-dimethylbiguanidato)-oxovanadium(IV), VO(metf)·HO, are potential agents against AD. A crucial step in drug design studies is obtaining information about the structure and interaction of these complexes with the biological targets involved in the process through molecular dynamics (MD) simulations. However, MD simulations depend on the choice of a good force field that could present reliable results. Moreover, general force fields are not efficient for describing the properties of metal complexes, and a VO(metf)·HO-specific force field does not yet exist; thus, the proper development of a parameter set is necessary. Furthermore, this investigation is essential and relevant given the importance for both the scientific community and the population that is affected by this neurodegenerative disease. Therefore, the present work aims to develop and validate the AMBER force field parameters for VO(metf)·HO since the literature lacks such information on metal complexes and investigate through classical molecular dynamics the interactions made by the complex with the protein. The proposed force field proved to be effective for describing the vanadium complex (VC), supported by different analyses and validations. Moreover, it had a great performance when compared to the general AMBER force field. Beyond that, MD findings provided an in-depth perspective of vanadium complex-protein interactions that should be taken into consideration in future studies.
世界上很大一部分人口受到阿尔茨海默病(AD)和 2 型糖尿病的影响,这两种疾病都造成了社会和经济影响。这两种情况都与一种蛋白质 AMPK 有关。研究表明,钒配合物,如双(','-二甲基双胍基)氧代钒(IV),VO(metf)·HO,是对抗 AD 的潜在药物。药物设计研究的关键步骤是通过分子动力学(MD)模拟获得有关这些配合物与涉及该过程的生物靶标相互作用结构和信息。然而,MD 模拟取决于选择一个能够提供可靠结果的良好力场。此外,一般力场对于描述金属配合物的性质并不有效,并且还不存在 VO(metf)·HO 特定的力场;因此,有必要开发一个合适的参数集。此外,鉴于该神经退行性疾病对科学界和受其影响的人群都很重要,因此进行这项研究非常重要。因此,本工作旨在开发和验证 AMBER 力场参数 VO(metf)·HO,因为文献中缺乏有关金属配合物的信息,并通过经典分子动力学研究配合物与蛋白质的相互作用。所提出的力场被证明对描述钒配合物(VC)有效,这得到了不同分析和验证的支持。此外,与一般的 AMBER 力场相比,它的性能也非常出色。除此之外,MD 研究结果提供了对钒配合物-蛋白质相互作用的深入了解,这在未来的研究中应该加以考虑。